# Remiges Ventures

Remiges Ventures is a Venture Capital based in Seattle, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Seattle, United States
- **Region:** North America
- **Address:** 1201 3rd Avenue, #2200, Seattle, WA 98101, United States
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** www.remigesventures.com
- **LinkedIn:** https://www.linkedin.com/company/remiges-ventures-inc

## Regulatory record

- **CRD number:** 175237
- **SEC file number:** 802-106758
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/175237

## About

Remiges Ventures is a venture firm that launched the RDiscovery Fund, focused on incubating drug discovery seeds. The firm lists a Seattle office for Remiges Ventures, Inc. and a Tokyo location for RDiscovery, KK. Its site features portfolio-related updates on companies including Immunis and Cyrano Therapeutics.

## Sectors

- Digital Health
- Healthcare Services

## Offices

- Tokyo, Japan
- Cambridge, MA, United States

## People

- Taro Inaba — Managing Partner
- Walter Olesiak — Operating Partner
- Takaaki Tobaru — Partner
- Taka Koda — Partner
- Stephen Gitto — Director of Finance
- Kazuhiko Nonomura — Partner
- Stuart Hwang — Venture Partner
- Linda Li — Venture Partner
- Kyoko Matsumoto — Senior Associate
- Naoki Hirayama — Investment Manager
- Mitsuhiko Kawai — Advisor
- Richard Meadows — Advisor

## Questions

### How does Remiges Ventures structure its drug-discovery incubation?

Remiges Ventures launched the RDiscovery Fund in April 2025 as a dedicated vehicle for incubating academic drug-discovery seeds. The fund operates through a Seattle office and a Tokyo office housed at the Global Life Science Hub, explicitly separating discovery-stage incubation from the firm's core venture capital activity. This bifurcated structure isolates early-stage scientific risk in a vehicle designed for nascent therapeutic programs.

### Does Remiges Ventures participate in fund commitments or only direct deals?

Remiges Ventures structures its activity primarily through direct venture creation and seed-stage investments, including its dedicated RDiscovery incubation vehicle. The firm's portfolio companies — such as Immunis and Cyrano Therapeutics — are direct positions rather than fund-of-funds allocations. No disclosures indicate an LP-in-funds program alongside its direct therapeutic company investments.

### How is the RDiscovery Fund related to the core venture platform?

The RDiscovery Fund is a distinct incubation vehicle operating under the Remiges Ventures umbrella with its own Tokyo-based management and a separate Seattle office address. It was launched in April 2025 to incubate drug-discovery seeds sourced from academic institutions, while the core venture platform continues to make direct therapeutic company investments. This structural separation isolates discovery-stage program risk from later-stage portfolio holdings.

## Related profiles

- [Remgro](https://altss.com/profile/remgro)
- [re.Mind Capital](https://altss.com/profile/re-mind-capital)

---

Last updated: 2026-08-11T15:07:57.118Z

Canonical page: https://altss.com/profile/remiges-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology